Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT-Reference-Cited by-同舟云学术

Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT

Published:2016-05-22 Issue:9 Volume:18 Page:1182-1189
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:Eur J Heart Fail

Author:

Komajda Michel¹,Tavazzi Luigi²,Swedberg Karl³,Böhm Michael⁴,Borer Jeffrey S.⁵,Moyne Aurélie⁶,Ford Ian⁷,

Affiliation:

1. Institute of Cardio-Metabolism and Nutrition (ICAN), Department of Cardiology; Pierre et Marie Curie University, Paris VI and Pitié-Salpêtrière Hospital; Paris France

2. Maria Cecilia Hospital, GVM Care & Research; E.S. Health Science Foundation; Cotignola Italy

3. Department of Molecular and Clinical Medicine, Sahlgrenska Academy; University of Gothenburg, Sweden, and National Heart and Lung Institute, Imperial College; London UK

4. Universitätsklinikum des Saarlandes, Klinik für Innere Medizin III, Homburg/Saar; Germany

5. Division of Cardiovascular Medicine, The Howard Gilman Institute for Heart Valve Diseases and the Schiavone Institute for Cardiovascular Translational Research; SUNY Downstate Medical Center, Brooklyn and New York; NY USA

6. Institut de Recherches Internationales Servier; Suresnes France

7. Robertson Centre for Biostatistics; University of Glasgow; UK

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Reference35 articles.

1. Improving care for patients with acute heart failure-before, during and after hospitalization;Cowie;ESC Heart Fail.,2014

2. EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot);Maggioni;Eur J Heart Fail,2013

3. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure;Solomon;Circulation,2007

4. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program;O'Connor;Am Heart J,2010

5. Risk following hospitalization in stable chronic systolic heart failure;Abrahamsson;Eur J Heart Fail,2013

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ivabradine Approved and Other Uses in Clinical Practice: A Systematic Review;Journal of Cardiovascular Pharmacology;2024-09

2. Cardiovascular and Renal Treatment in Heart Failure Patients with Hyperkalemia or High Risk of Hyperkalemia: Rationale and Design of the CARE-HK in HF Registry;Journal of Cardiac Failure;2024-09

3. Vulnerable period in heart failure: a window of opportunity for the optimization of treatment – a statement by Mexican experts;Drugs in Context;2024-01-16

4. Resumen ejecutivo de la actualización 2023 del consenso de actuación básica durante el ingreso hospitalario por insuficiencia cardiaca aguda;Revista Clínica Española;2023-10

5. Executive summary of the 2023 update on the consensus regarding basic conduct during hospital admission for patients with acute heart failure;Revista Clínica Española (English Edition);2023-10